Truist reiterates Buy on Boston Scientific stock amid 2027 outlook

Truist reiterated a Buy rating and $51 price target on Boston Scientific after the company’s updated outlook, which incorporates negative growth in 2027 following a late-August cyberattack and delays pipeline catalysts to 2028. The remaining 75% of the portfolio is expected to grow about 5% in 2027, with total revenue growth of 6–7% or more in 2028; shares were $42.13, down 55% year to date. Recent Q3 results included adjusted EPS of $0.73 versus $0.75 expected and revenue of $5.14 billion, while the cyber incident was estimated to have reduced organic growth by 300 basis points, or about $150 million, and adjusted EPS by $0.07.

Analysis

The key risk is not simply the one-time cyber disruption: it is the possibility that lost manufacturing and shipping time compounds into delayed launches, weaker physician adoption, and share leakage while the pipeline is pushed out. That makes the 2028 recovery dependent on execution rather than just easier comparisons. The unaffected portfolio’s expected growth may cushion the trough, but does not establish that delayed products will regain their prior revenue trajectory.

The “de-risked” framing is potentially premature. Estimates now include a weak 2027, but further revisions remain possible if the disruption persists or electrophysiology, Watchman, or China trends deteriorate beyond management’s assumptions. Conversely, if operations normalize and launch timelines hold, the depressed setup could support a recovery well before 2028 as forward estimates stabilize. The cited P/E and PEG are backward-looking signals in a period of shifting growth estimates; the PEG is especially unreliable when the near-term growth denominator is disrupted.

Competitors including Abbott, Medtronic, and Edwards Lifesciences could benefit if BSX delays create openings in physician workflows, though product-level switching and share data are needed to establish durable gains. The Oppenheimer downgrade is an analyst call, not evidence of a direct earnings impact to Oppenheimer Holdings (OPY).

Key Decisions for Investors

• Avoid treating the low-$40 share price or analyst price targets as a floor. For a 1–3 month horizon, stay neutral or scale in only after evidence that production, shipping, and organic growth are recovering; the near-term risk is another estimate reset.
• Watch the next earnings update for cyber-related operational normalization, organic growth by business, and confirmation of product launch timing. Any renewed disruption, further 2027 estimate cuts, or slippage in launches falsifies the recovery thesis; stable execution with estimates no longer falling would support adding exposure.
• For a relative-value expression, consider a small BSX-underweight versus a diversified medtech basket rather than an outright short: this limits exposure to broad sector moves while the duration of share leakage is unproven. Reassess once product-level share and launch data are available.
• Over 6–18 months, the upside case is a return to growth as delayed catalysts arrive; the downside is that a presumed temporary interruption becomes persistent competitive loss. Do not underwrite the recovery until management demonstrates operational normalization and the 2028 launch calendar remains intact.